Ryan Specialty Q3 2026 Organic Growth Slows to 4%, Far Below Guidance

What happened

Ryan Specialty reported Q3 2026 revenue of $790 million, up only 4.7% year-over-year, with organic growth of just 4%, a sharp drop from the 9-11% target range the company had guided for fiscal 2025 and far below the 6-8% bear case scenario outlined in earlier analysis. The weak organic performance was partially offset by contributions from acquisitions and contingent commissions, but these one-off items could not mask the underlying slowdown in core wholesale and binding authority placements. Adjusted EBITDAC increased 3.8% to $244 million, implying continued margin compression as revenue growth outpaced profit growth, consistent with prior warnings about heavy talent spending and a softening property insurance market. Adjusted earnings per share rose 8.5% to $0.51, but this improvement was driven more by financial engineering (lower share count or tax benefits) than by operational leverage, and it remains well below the double-digit growth investors had come to expect. This result validates concerns raised in the February 2026 deep value report that organic growth volatility and margin pressure were not temporary, and that the company's reliance on acquisitions to sustain reported growth is masking underlying weakness.

Implication

Investors should reduce exposure to Ryan Specialty until the company demonstrates a sustainable return to at least high single-digit organic growth, as the current 4% print suggests the property softness and retailer direct placement headwinds are more persistent than management previously indicated. The continued margin compression despite modest revenue growth indicates that the talent investments made over the past year are not yet generating sufficient returns, raising questions about the effectiveness of the growth strategy. With adjusted EPS growth of only 8.5% and a high leverage ratio (net debt/EBITDA of 4.88x and interest coverage of 1.9x as of early 2026), the stock's premium valuation is no longer justified by fundamentals. The next few quarters will be critical; if organic growth remains below 5% and margin does not stabilize, the bear case scenario implying a valuation closer to $32 per share becomes more probable. Long-term investors should monitor whether management revises guidance downward or announces structural changes, as continued underperformance could lead to credit rating pressures and reduced financial flexibility.

Thesis delta

The original WAIT thesis was predicated on organic growth holding at 9-11% with margin stabilization; Q3 2026's 4% organic growth and 3.8% EBITDAC growth break that assumption materially. This shifts the probability weight toward the bear case, which projected organic growth of 6-8%, but even that may now be optimistic given the actual result. The investment case now hinges on the company's ability to quickly reverse the slowdown, which appears unlikely without a significant change in market conditions or strategy.